On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

PD-1 Checkpoint Inhibitors Harness the Immune System to Treat Lymphomas

A new class of drugs, known as immune checkpoint inhibitors, is providing new perspective on how to treat relapsed and refractory lymphomas, according to...

CAR T Therapies: Engineering a Breakthrough in Lymphoma and Leukemia Treatment

Novel therapies that harness the body’s own immune cells to attack cancer cells took center stage at this year’s annual meeting. Across a variety of...

Venetoclax Plus Low-Dose Cytarabine Safe and Effective in Older Patients With Acute Myeloid Leukemia

The combination of the selective BCL-2 inhibitor venetoclax and low-dose cytarabine (LDAC) is a safe, effective option in older patients with acute myeloid leukemia...

ASH 2014 Annual Meeting Preview: The Rising Cost of Medical Care

Understanding the Problems and Exploring Solutions Health-care spending in the United States is a growing problem: in 2011, health-care spending was estimated at $2.7 trillion,...

Age, Comorbidity, Time on Chemotherapy Predict Increases in Hospitalizations, ER Visits Among CLL Patients

Researchers identified several risk factors leading to greater health-care resource use, including age, comorbidity burden, presence of adverse events, and duration of therapy, in...

Nilotinib Improves Prognosis in Elderly Patients with Ph+ ALL

For the difficult-to-treat elderly population (aged ≥55 years) with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL), combining age-adapted, low-intensity chemotherapy with nilotinib is...

Age, Sex, Timing of Treatment Response Predict Avascular Necrosis in Children with ALL

Avascular necrosis (AVN), a disorder resulting from a temporary or permanent loss of blood supply to the bone, is one of the most serious...
On location

Ibrutinib Well Tolerated in Patients With Central Nervous System Lymphoma

CHICAGO--With few treatment options available for central nervous system lymphoma (CNSL), patients with recurrent/refractory disease typically have poor outcomes, with response rates ranging between...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat a patient with nodular...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

2014 ASH Annual Meeting: Late But Certainly Not Least…

This year’s six late-breaking abstracts feature innovative research in preventing bleeding risk, better prediction tools in Hodgkin lymphoma, and new approaches for high-risk, difficult-to-treat...
Advertisement

Current Issue

November 2020 Bonus ASH Annual Meeting Preview Edition (Volume 6, Issue...

View issue flipbook November 2020 Bonus ASH Annual Meeting Preview Edition Volume 6, Issue 14This issue offers a behind-the-scenes look at this year's virtual annual meeting,...

Block title